Xilio Therapeutics, Inc. Earnings Per Share (Basic)
Xilio Therapeutics, Inc. (XLO) reported Earnings Per Share (Basic) of -$0.33 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-12
- Xilio Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$0.33.
- Xilio Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$0.58.
- Xilio Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-12-31 was -$0.04, a 137.52% decline year-over-year.
- Xilio Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$0.11.
- Xilio Therapeutics, Inc. earnings per share, basic for fiscal 2025 was -$4.19.
- Xilio Therapeutics, Inc. earnings per share, basic for fiscal 2024 was -$15.24.
- Xilio Therapeutics, Inc. earnings per share, basic for fiscal 2023 was -$2.78.
- Xilio Therapeutics, Inc. earnings per share, basic for fiscal 2022 was -$3.22.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 6 month as first filed | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month | Earnings Per Share, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$0.33 10-Q · filed 2026-08-12 | -$0.89 10-Q · filed 2026-08-12 | $0.07 derived: net income ÷ weighted average shares · filed 2026-08-12 | $0.85 derived: net income ÷ weighted average shares · filed 2026-08-12 | |||
| 2026-03-31 | -$0.58 10-Q · filed 2026-05-12 | -$0.01 derived: net income ÷ weighted average shares · filed 2026-05-12 | $0.38 derived: net income ÷ weighted average shares · filed 2026-05-12 | $1.09 derived: net income ÷ weighted average shares · filed 2026-08-12 | |||
| 2025-12-31 | -$0.04 derived: net income ÷ weighted average shares · filed 2026-03-23 | $0.09 derived: net income ÷ weighted average shares · filed 2026-03-23 | $0.50 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$4.19 10-K · filed 2026-03-23 | |||
| 2025-09-30 | -$0.11 10-Q · filed 2025-11-13 | -$0.43 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$0.43 10-Q · filed 2025-11-13 | -$10.48 derived: net income ÷ weighted average shares · filed 2026-08-12 | |||
| 2025-06-30 | -$2.30 10-Q · filed 2026-08-12 | -$0.16 10-Q · filed 2025-08-14 | -$4.76 10-Q · filed 2026-08-12 | -$0.34 10-Q · filed 2025-08-14 | $1.04 derived: net income ÷ weighted average shares · filed 2026-08-12 | $3.86 derived: net income ÷ weighted average shares · filed 2026-08-12 | |
| 2025-03-31 | -$2.49 10-Q · filed 2026-05-12 | -$0.18 10-Q · filed 2025-05-08 | $0.41 derived: net income ÷ weighted average shares · filed 2026-05-12 | $1.86 derived: net income ÷ weighted average shares · filed 2026-05-12 | $29.20 derived: net income ÷ weighted average shares · filed 2026-05-12 | ||
| 2024-12-31 | $0.10 derived: net income ÷ weighted average shares · filed 2026-03-23 | $0.77 derived: net income ÷ weighted average shares · filed 2026-03-23 | $9.64 derived: net income ÷ weighted average shares · filed 2026-03-23 | -$15.24 10-K · filed 2026-03-23 | -$1.09 10-K · filed 2025-03-11 | ||
| 2024-09-30 | -$0.22 10-Q · filed 2025-11-13 | -$0.46 derived: net income ÷ weighted average shares · filed 2025-11-13 | -$0.91 10-Q · filed 2025-11-13 | -$1.42 derived: net income ÷ weighted average shares · filed 2025-11-13 | |||
| 2024-06-30 | -$0.24 10-Q · filed 2025-08-14 | -$0.73 10-Q · filed 2025-08-14 | -$1.29 derived: net income ÷ weighted average shares · filed 2025-08-14 | -$1.86 derived: net income ÷ weighted average shares · filed 2025-08-14 | |||
| 2024-03-31 | -$0.62 10-Q · filed 2025-05-08 | -$1.26 derived: net income ÷ weighted average shares · filed 2025-05-08 | -$1.87 derived: net income ÷ weighted average shares · filed 2025-05-08 | -$2.57 derived: net income ÷ weighted average shares · filed 2025-05-08 | |||
| 2023-12-31 | -$0.64 derived: net income ÷ weighted average shares · filed 2025-03-11 | -$1.25 derived: net income ÷ weighted average shares · filed 2025-03-11 | -$1.95 derived: net income ÷ weighted average shares · filed 2025-03-11 | -$2.78 10-K · filed 2025-03-11 | |||
| 2023-09-30 | -$0.61 10-Q · filed 2024-11-07 | -$1.31 derived: net income ÷ weighted average shares · filed 2024-11-07 | -$2.14 10-Q · filed 2024-11-07 | -$2.96 derived: net income ÷ weighted average shares · filed 2024-11-07 | |||
| 2023-06-30 | -$0.70 10-Q · filed 2024-08-08 | -$1.53 10-Q · filed 2024-08-08 | -$2.35 derived: net income ÷ weighted average shares · filed 2024-08-08 | -$3.07 derived: net income ÷ weighted average shares · filed 2024-08-08 | |||
| 2023-03-31 | -$0.83 10-Q · filed 2024-05-14 | -$1.64 derived: net income ÷ weighted average shares · filed 2024-05-14 | -$2.37 derived: net income ÷ weighted average shares · filed 2024-05-14 | -$3.27 derived: net income ÷ weighted average shares · filed 2024-05-14 | |||
| 2022-12-31 | -$0.82 derived: net income ÷ weighted average shares · filed 2024-04-01 | -$1.54 derived: net income ÷ weighted average shares · filed 2024-04-01 | -$2.44 derived: net income ÷ weighted average shares · filed 2024-04-01 | -$3.22 10-K · filed 2024-04-01 | |||
| 2022-09-30 | -$0.72 10-Q · filed 2023-11-09 | -$1.62 derived: net income ÷ weighted average shares · filed 2023-11-09 | -$2.40 10-Q · filed 2023-11-09 | -$3.34 derived: net income ÷ weighted average shares · filed 2023-11-09 | |||
| 2022-06-30 | -$0.90 10-Q · filed 2023-08-14 | -$1.68 10-Q · filed 2023-08-14 | -$2.63 derived: net income ÷ weighted average shares · filed 2023-11-09 | -$4.33 derived: net income ÷ weighted average shares · filed 2023-11-09 | |||
| 2022-03-31 | -$0.78 10-Q · filed 2023-05-09 | -$1.73 derived: net income ÷ weighted average shares · filed 2023-11-09 | -$3.56 derived: net income ÷ weighted average shares · filed 2023-11-09 | -$6.56 derived: net income ÷ weighted average shares · filed 2023-11-09 | |||
| 2021-12-31 | -$0.97 derived: net income ÷ weighted average shares · filed 2023-03-02 | -$3.43 derived: net income ÷ weighted average shares · filed 2023-03-02 | -$8.17 derived: net income ÷ weighted average shares · filed 2023-03-02 | -$13.52 10-K · filed 2023-03-02 | |||
| 2021-09-30 | -$21.27 10-Q · filed 2022-11-09 | -$52.56 derived: net income ÷ weighted average shares · filed 2022-11-09 | -$76.18 10-Q · filed 2022-11-09 | -$107.18 derived: net income ÷ weighted average shares · filed 2022-11-09 | |||
| 2021-06-30 | -$31.48 10-Q · filed 2022-08-09 | -$55.16 10-Q · filed 2022-08-09 | -$86.39 derived: net income ÷ weighted average shares · filed 2022-11-09 | -$111.03 derived: net income ÷ weighted average shares · filed 2022-11-09 | |||
| 2021-03-31 | -$23.53 10-Q · filed 2022-05-12 | -$54.71 derived: net income ÷ weighted average shares · filed 2022-11-09 | -$79.13 derived: net income ÷ weighted average shares · filed 2022-11-09 | ||||
| 2020-12-31 | -$31.46 derived: net income ÷ weighted average shares · filed 2022-03-01 | -$55.92 derived: net income ÷ weighted average shares · filed 2022-03-01 | -$105.42 10-K · filed 2022-03-01 | ||||
| 2020-09-30 | -$24.19 10-Q · filed 2021-12-02 | -$72.02 10-Q · filed 2021-12-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 |